Long-term Safety and Effectiveness of Growth Hormone With GHD, TS, CRF, SGA , ISS and PWS in Children

ConditionsGrowth Hormone Deficiency Turner Syndrome Chronic Renal Failure Small for Gestational Age Idiopathic Short Stature

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age2+

SponsorLG Chem

About this trial

The purpose of this study is to evaluate the long-term safety and effectiveness of growth hormone (Eutropin Inj./Eutropin plus Inj.) treatment with GHD (Growth Hormone Deficiency), TS (Turner Syndrome),CRF (Chronic Renal Failure), SGA (Small for Gestational Age), and ISS (Idiopathic Short Stature).

Eligibility criteria

Qualifiers

short stature children aged 2 years or more

children with GHD,TS, CRF, SGA or ISS

written informed consent from the person, person's parent or legal guardian

Disqualifiers

None

Trial design

Treatments tested in this trial

Not listed

Trial groups

6,000 Participants

are grouped into 1 trial group

Sponsors and collaborators

LG Chem

Lead sponsor

Source ClinicalTrials.gov